These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29318515)

  • 21. [Understanding and reducing the risk of adverse drug reactions in pediatric patients].
    Gotta V; van den Anker J; Pfister M
    Ther Umsch; 2015 Dec; 72(11-12):679-86. PubMed ID: 26654811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interrater reliability of the modified Monitoring of Side Effects Scale for assessment of adverse effects of psychiatric medication in clinical and research settings.
    Nugent KL; Spahr E; Toroney J; Mojtabai R; Nettles C; Turner LW; Fenton A; Spivak A; Cullen BA; Everett A; Eaton WW
    J Clin Psychopharmacol; 2015 Jun; 35(3):324-8. PubMed ID: 25928700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology.
    Blair J; Taggart B; Martin A
    J Neural Transm (Vienna); 2004 Jul; 111(7):791-815. PubMed ID: 15205999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (MOPHAR) monitoring program - a study protocol.
    Simoons M; Ruhé HG; van Roon EN; Schoevers RA; Bruggeman R; Cath DC; Muis D; Arends J; Doornbos B; Mulder H
    BMC Health Serv Res; 2019 Feb; 19(1):125. PubMed ID: 30764821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The importance of therapeutic drug monitoring for psychotropic drugs].
    Messer T; Schmauss M
    MMW Fortschr Med; 2006 May; Spec no. 2():91-2, 94-5. PubMed ID: 20104722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges.
    Vitiello B
    Psychopharmacology (Berl); 2007 Mar; 191(1):5-13. PubMed ID: 16718480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are non-serious adverse reactions to psychiatric drugs really non-serious?
    Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nocebo effects and psychotropic drug action.
    Amanzio M
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):159-61. PubMed ID: 25494811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug safety in psychiatry--an objective for drug monitoring in phase IV.
    Schmidt LG; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1984 Sep; 17(5):152-6. PubMed ID: 6494244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective assessment of psychotropic medication side effects using PsyLOG mobile application.
    Rojnic Kuzman M; Andlauer O; Burmeister K; Dvoracek B; Lencer R; Koelkebeck K; Maric NP; Nawka A; Pantovic-Stefanovic M; Riese F; Aukst Margetic B; Bosnjak D; Ruzic MC; Curkovic M; Grubsin J; Madzarac Z; Makaric P; Petric D; Radic K; Savic A
    Schizophr Res; 2018 Feb; 192():211-212. PubMed ID: 28457773
    [No Abstract]   [Full Text] [Related]  

  • 32. The AMSP drug safety program: methods and global results.
    Grohmann R; Engel RR; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S4-11. PubMed ID: 15052509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The way towards adverse event monitoring in clinical trials.
    Wallander MA
    Drug Saf; 1993 Mar; 8(3):251-62. PubMed ID: 8452665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder.
    Kim JH; Choi SW; Joe SH; Ha TH; Yoo HJ; Choi JE; Cha B; Ha K
    Nord J Psychiatry; 2008; 62(6):496-502. PubMed ID: 18841509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives.
    Persico AM; Arango C; Buitelaar JK; Correll CU; Glennon JC; Hoekstra PJ; Moreno C; Vitiello B; Vorstman J; Zuddas A;
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1513-31. PubMed ID: 26166453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serious adverse event reporting in investigator-initiated clinical trials.
    Wallace S; Myles PS; Zeps N; Zalcberg JR
    Med J Aust; 2016 Apr; 204(6):231-3. PubMed ID: 27031396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.